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Abstract
Abundantly expressed in pain-sensing neurons, TRPV1, TRPA1 and TRPM8 are major cellular
sensors of thermal, chemical and mechanical stimuli. The function of these ion channels has been
attributed to their selective permeation of small cations (e.g., Ca2+, Na+ and K+), and the ion
selectivity has been assumed to be an invariant fingerprint to a given channel. However, for TRPV1,
the notion of invariant ion selectivity has been revised recently. When activated, TRPV1 undergoes
time and agonist-dependent pore dilation, allowing permeation of large organic cations such as Yo-
Pro and NMDG+. The pore dilation is of physiological importance, and has been exploited to
specifically silence TRPV1-positive sensory neurons. It is unknown whether TRPA1 and TRPM8
undergo pore dilation. Here we show that TRPA1 activation by reactive or non-reactive agonists
induces Yo-Pro uptake, which can be blocked by TRPA1 antagonists. In outside-out patch
recordings using NMDG+ as the sole external cation and Na+ as the internal cation, TRPA1
activation results in dynamic changes in permeability to NMDG+. In contrast, TRPM8 activation
does not produce either Yo-Pro uptake or significant change in ion selectivity. Hence, pore dilation
occurs in TRPA1, but not in TRPM8 channels.
Background
Abundantly expressed in sensory neurons, TRPV1, TRPA1
and TRPM8 are involved in sensory function, pain and
neurogenic inflammation [1]. The function of these ion
channels has been attributed to their ability to pass certain
ion species across the plasma membrane. Once activated,
TRPV1, TRPA1 and TRPM8 are permeable to small cations
such as Ca2+, K+, Na+; hence, channel activation simulta-
neously depolarizes the plasma membrane and raises
intracellular Ca2+, which subsequently triggers a variety of
physiological processes. By analogy to voltage-gated K+
channels, it is assumed that ion selectivity of TRP channels
should be an invariant signature to the respective channel.
However, this notion has been challenged recently. When
activated, TRPV1 exhibits time and agonist-dependent
changes in ion selectivity [2]. In fact, TRPV1 undergoes
pore dilation and allows permeation of large organic cati-
ons, including spermine (202.3 Da), NMDG (195.2 Da),
Yo-Pro (376 Da), gentamycin (477.6 Da) and QX-314 [3-
7]. Here we explored whether TRPA1 and TRPM8 undergo
pore dilation by examining Yo-Pro uptake and changes in
ion selectivity upon channel activation.
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Results and discussion
Yo-Pro is a divalent cation impermeable to the plasma
membrane. However, under certain conditions, it can
enter cells, bind nucleic acids and emit fluorescence.
Hence the uptake of Yo-Pro has been used previously as
an indicator of pore dilation [2,8,9]. In HEK293-F cells
transiently expressing rat TRPA1, allyl isothiocyanate
(AITC) evoked robust increases in intracellular Ca2+ (Fig.
1A). Concomitantly, AITC also induced Yo-Pro uptake in
a concentration-dependent manner (Fig. 1B). At higher
concentrations of AITC (100 or 300 μM), the increase in
fluorescence was immediately noticeable and continued
to increase for about 50 min. In addition, AITC also
induced Ca2+ influx and Yo-Pro uptake in cells expressing
human TRPA1 and mouse TRPA1, but not in untrans-
fected cells (data not shown). In cells expressing human
TRPM8, menthol activated TRPM8 as indicated by the
concentration-dependent Ca2+ influx, but failed to induce
Yo-Pro uptake (Fig. 1C and 1D). Other TRPM8 agonists
(e.g., icilin) also evoked Ca2+ influx but failed to induce
Yo-Pro uptake (data not shown). Hence, Yo-Pro uptake
occurs upon activation of TRPA1, but not TRPM8.
In addition to AITC, TRPA1 can be activated by many
other electrophilic agonists (e.g., cinnamaldehyde or CA,
4-hydroxynonenal or 4-HNE), and non-reactive agonists
(e.g., URB597, farnesyl thiosalicylic acid or FTS) [10-14].
We investigated whether the Yo-Pro uptake is limited to
AITC. CA, 4-HNE, FTS and URB597 all evoked Ca2+ influx
and Yo-Pro uptake in a concentration dependent-manner
(Fig. 2A and 2B). In the Ca2+ assay, the EC50 was 6.5 ± 0.35
μM for AITC, 6.8 ± 1.5 μM for CA, 4.4 ± 0.6 μM for 4-HNE,
33.2 ± 8.1 μM for FTS and 85.6 ± 10.4 μM for URB597 (n
= 4–8). Compared to AITC, the maximal signals were
104% for CA, 88% for 4-HNE, 107% for FTS and 82% for
URB597. In the Yo-Pro uptake assay, the EC50 was 16.0 ±
3.8 μM for AITC, 5.9 ± 0.7 μM for CA, 7.1 ± 0.2 μM for 4-
HNE, 41.8 ± 10.7 μM for FTS and 85.4 ± 19.8 μM for
URB597 (n = 4–8). Compared to AITC, the maximal sig-
nals were 98% for CA, 82% for 4-HNE, 117% for FTS and
The activation of TRPA1, but not TRPM8, induced Yo-Pro  uptake Figure 1
The activation of TRPA1, but not TRPM8, induced 
Yo-Pro uptake. A, in HEK-293F cells expressing rat 
TRPA1, AITC elevated intracellular Ca2+, as represented by 
increases of fluorescence signals (RFU) in the FLIPR based 
Ca2+ assay. B, in cells expressing TRPA1, AITC evoked 
robust Yo-Pro uptake in a concentration-dependent manner 
from the FLIPR based Yo-Pro uptake assays. C, in cells 
expressing human TRPM8, menthol activated TRPM8 and 
elevated intracellular Ca2+. D, in cells expressing TRPM8, 
menthol failed to induce Yo-Pro uptake. Compounds are in 
μM and additions are indicated by arrows.
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Yo-Pro uptake was evoked by various TRPA1 agonists and  blocked by TRPA1 antagonists Figure 2
Yo-Pro uptake was evoked by various TRPA1 ago-
nists and blocked by TRPA1 antagonists. Concentra-
tion-effect relationships for agonist responses in the Ca2+ 
assay (A) and Yo-Pro uptake (B). Reactive agonists: AITC, 
CA and 4-HNE. Non-reactive agonists: FTS and URB597. 
Data are represented as percentage of maximal AITC 
responses. C, representative traces of Yo-Pro uptake in 
response to a first addition of AP18 (0 to 100 μM) and a sec-
ond addition of AITC (30 μM). AP18 inhibited AITC evoked 
Yo-Pro uptake in a concentration-dependent manner. D, 
concentration-effect relationship of Yo-Pro uptake inhibition 
by AP18, HC-030031 and RR. (n = 4 – 8).
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84% for URB597, respectively. Hence, TRPA1 activation
by different agonists all induced Yo-Pro uptake.
Several small molecule inhibitors of TRPA1 have been
described recently, including AP18, HC-030031 and
ruthenium red (RR) [15,16]. We tested whether these
antagonists blocked Yo-Pro uptake. AP18 attenuated 30
μM AITC-induced Yo-Pro uptake in a concentration-
dependent manner, with an IC50 of 10.3 ± 0.8 μM (Fig. 2C
and 2D). Likewise, HC-030031 and RR also completely
blocked Yo-Pro uptake (IC50: 9.4 ± 0.6 μM for HC-030031
and 10.0 ± 1.6 μM for RR). Taken together, these data
show that agonist-evoked Yo-Pro uptake is related to
TRPA1 channel activities.
Next, we investigated whether TRPA1 undergoes changes
in ion selectivity upon channel activation. Currents were
recorded under the outside-out patch configuration using
NMDG+ as the sole external cation and Na+ as the major
internal cation. Patch membrane potential was held at -80
mV, and a ramp voltage from -140 mV to 0 mV (500 ms
duration) was applied every 3 seconds. Before addition of
AITC, a small basal current was present, consistent with
previous reports [17,18]. The reversal potential (Erev) of
basal currents was -95.3 ± 4.8 mV (n = 5). Compared to
activation of TRPV1 by capsaicin, activation of TRPA1 by
AITC was relatively slow, probably due to the covalent
reaction that is needed to activate TRPA1. Addition of
AITC (100 μM) elicited gradual activation of TRPA1 and
rightward shift in reversal potential (Fig. 3A). The shift in
Erev occurred as early as 6 s following addition of AITC,
and continued to increase with nearly maximum shift at
~15 s. Addition of 10 μM RR nearly completely blocked
AITC-evoked NMDG+ and Na+ currents (Fig. 3A inset),
indicating the observed currents were mediated by TRPA1
channels.
In contrast, TRPM8 showed no shift in Erev following addi-
tion of 500 μM menthol, despite a clear increase in current
(Fig. 3B). The time-dependent changes in Erev for TRPA1
and TRPM8 following their activation are shown in Fig.
4A. The shift in Erev for TRPA1 was not due to an increase
in anion selectivity, as removal of Cl- in the bath solution
caused a similar shift in Erev from -96 mV to -42 mV. From
Erev values, permeability ratios (PNMDG/PNa) before and 60
s after agonist addition were derived. As shown in Fig. 4B,
PNMDG/PNa increased ~4.4-fold for TRPA1 from 0.05 ±
0.003 to 0.22 ± 0.013 (n = 4, P < 0.05, paired t-test), com-
parable to the ~5.5 fold increase reported for TRPV1 [2].
In contrast, PNMDG/PNa did not change significantly for
TRPM8. It is interesting that the shift in Erev occurred
much earlier than the increase in TRPA1 currents (Fig.
4C), indicating that pore dilation occurs well before max-
imal channel activation.
The accuracy of Erev measurement could be compromised
by small current amplitudes, especially for basal currents
and currents immediately following AITC application.
However, the Erev of basal currents was consistent across
patches (-95.3 ± 4.8 mV, n = 5), and Erev shifts consistently
occurred in TRPA1, but not in TRPM8. In addition, even
for relatively large TRPA1 currents, significant shifts in Erev
occurred. For example, the shift in Erev  was 31.6 mV
between 6 s and 15 s pulses, and 14.2 mV between 9 s and
Ionic currents of TRPA1, but not TRPM8, exhibited shifts in  reversal potential Figure 3
Ionic currents of TRPA1, but not TRPM8, exhibited 
shifts in reversal potential. Outside-out patches were 
formed from HeLa cells expressing rat TRPA1 or human 
TRPM8 plus GFP. NMDG+ was the sole external cation and 
Na+ was the major internal cation. Membrane potential was 
held at -80 mV, and a voltage ramp from -140 to 0 mV (500 
ms duration) was applied every 3 s immediately. A, current 
traces from a representative TRPA1-containing patch during 
60 s application of AITC (100 μM). To illustrate shifts in Erev, 
only currents between -6 to 8 pA were plotted. Inset shows 
the AITC-evoked currents were almost completely blocked 
by 10 μM RR. B, currents from a representative TRPM8-con-
taining patch during 60 s application of menthol (500 μM). 
Note the shifts in Erev for TRPA1, but no shift for TRPM8.
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15 s pulses (Fig. 3A and 4A). Taken together, these data
suggests that the dynamic change in Erev results from
TRPA1 channel activity. Another concern in extrapolating
the change in Erev to the change in ion selectivity is that
ion accumulation can occur during prolonged activation,
particularly when large currents are conducted under
whole cell configuration. However, the ion accumulation
should not significantly compromise our TRPA1 experi-
ments using outside-out patch configuration, in which
extracellular and intracellular ionic conditions were well
controlled. In addition, reversal potentials changed
within seconds of AITC application when currents were
small, but reached a steady state (from 15 to 60 s) when
currents were relatively large (Fig. 3A and 4A). Further-
more, TRPM8 conducted currents with similar amplitudes
but without significant shifts in reversal potential. Con-
sistent with the electrophysiology data, the large divalent
cation Yo-Pro did not cross the membrane when the chan-
nel was closed or blocked by antagonists, but permeated
the membrane freely when the channel was open (Fig. 1B
and 2C). Collectively, our data suggest that TRPA1, but
not TRPM8, undergoes pore dilation.
Pore dilation has been previously described for the ATP-
gated P2X and TRPV1 [2,8,9]. For P2X channels, the
mechanism underlying pore dilation remains controver-
sial. Several alternative mechanisms have been proposed
including a direct change in ion selectivity, formation of
channel multimers, and recruitment of a downstream,
nonselective pore [19,20]. For TRPV1, pore dilation most
likely arises from a change in ion selectivity, as indicated
by the dynamic change in ion selectivity during agonist
stimulation, and the effects of mutations and chemical
modification of certain residues within the selectivity fil-
ter [2]. In the current study, we did not elucidate the bio-
physical mechanism underlying pore dilation of TRPA1.
However, there were several notable observations. First,
the permeability to NMDG+ increased almost immedi-
ately upon channel activation. Second, the outside-out
patch configuration should largely disrupt cytoskeletal
structures and washout cytosolic factors. Third, the AITC
evoked- NMDG+ and Na+ conductance was sensitive to
blockade by ruthenium red. Finally, under identical con-
ditions, TRPM8 conducted large currents, but did not
exhibit Yo-Pro uptake or a significant change in NMDG+
permeability. Thus, TRPA1 pore dilation most likely rep-
resents a direct change in ion selectivity. Nonetheless, our
present study does not completely rule out the involve-
ment of other proteins.
TRPV1, TRPA1 and TRPM8 are major TRP channels
involved in somatosensation. Within dorsal root ganglia,
TRPV1 and TRPA1 are co-expressed and interact function-
ally in one population of sensory neurons, while TRPM8
is expressed largely in a separate neuronal population.
Interestingly, pore dilation occurs in TRPA1, TRPV1 but
not TRPM8, suggesting that this property is not ubiqui-
tous, but rather specific to subtypes of channels within a
subpopulation of neurons. The change in cation permea-
bility, in turn, may alter channel function, affect a host of
downstream processes (e.g., neurotransmitter release, cel-
Time-dependent changes in ion permeability occurred in  TRPA1 but not in TRPM8 Figure 4
Time-dependent changes in ion permeability 
occurred in TRPA1 but not in TRPM8. A, Erev values 
were determined (from Fig. 3 experiments) and plotted as a 
function of time after application of AITC or menthol. B, per-
meability ratios (PNMDG/PNa) before and 60 s after agonist 
addition. Student's t-test was used with p < 0.05 as the crite-
rion for significance (indicated by *). C, changes in Erev and 
relative currents at 0 mV (from representative recordings) 
were plotted as a function of time after application of AITC. 
Outward currents were measured at 0 mV and normalized 
against the current obtained after 60 s addition of AITC.
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lular toxicity) and contribute to pain hypersensitivity [21].
Recently, it was reported that TRPV1-mediated pore dila-
tion could be utilized to deliver QX-314 (a membrane-
impermeant sodium channel blocker) specifically to
TRPV1-positive sensory neurons, achieving analgesic
effects without motor deficits associated with local anes-
thetics [5]. However, this strategy of targeting TRPV1-pos-
itive neurons could be compromised by several factors,
including the broad expression pattern of TRPV1, its role
in regulating body temperature, and its involvement in
hippocampal synaptic plasticity [22,23]. By analogy to
TRPV1, the pore dilation of TRPA1 could be exploited to
mediate entry of QX-314 specifically into TRPA1-positive
neurons. Given the restrictive expression of TRPA1 in sen-
sory neurons, this strategy may offer analgesic efficacy
without unwanted side effects.
In conclusion, the present study demonstrates that pore
dilution occurs in TRPA1 but not in TRPM8 channels. This
finding raises many interesting questions: What is the
exact biophysical mechanism underlying pore dilation of
TRPA1? What are the physiological, pathological and ther-
apeutic implications? Why does pore dilation not occur in
TRPM8? What are the pore behaviors of other TRP chan-
nels? Answers to these questions will certainly extend our
understanding of this family of ion channels.
Methods
Transient expression of recombinant TRPs
Full length cDNAs for rat TRPA1(GenBank Accession:
NM_207608), human TRPA1 (NM_007332), mouse
TRPA1 (NM_177781) and human TRPM8 (NM_024080)
were cloned into pcDNA3.1/V5-His TOPO vector and
transiently expressed in HEK293-F or HeLa cells [24]. For
the Ca2+ influx or Yo-Pro uptake assay, HEK293-F cells
were transfected with TRP cDNA, collected 48 hours post
transfection, and used either fresh or following storage at
-70°C. For electrophysiological experiments, HeLa cells
were transfected with TRPA1 or TRPM8 plus GFP, and
used 48 hours later.
Ca2+ influx and Yo-Pro uptake assays
Ca2+ influx assay was performed using the FLIPR™ and cal-
cium assay kit R8033 (MDS Analytical Technology) as
reported previously [25]. After incubation with 100 μl of
1 × Ca2+ dye for ~2 hours at room temperature, a two-
addition protocol was used for evaluating agonist activi-
ties (i.e., activation of Ca2+ influx) and antagonist activi-
ties (i.e., inhibition of agonist responses): 10 s baseline
readout, addition of 50 μl assay buffer or antagonist (4 ×
stock), 3–4 min readout, addition of 50 μl agonist (4 ×
stock), and readout for 2.5 min. Maximum minus mini-
mum signals before the second addition and at the end of
the experiment were obtained.
Yo-Pro uptake was determined using the FLIPR™ and
Mg2+/Ca2+-free DPBS buffer as reported previously [26].
Briefly, immediately after loading with 100 μl Yo-Pro dye
(2 μM), a two-addition protocol was used for evaluating
agonist activity (i.e., Yo-Pro uptake) and antagonist activ-
ities (i.e., inhibition of agonist evoked Yo-Pro uptake): 10
s baseline readout, addition of 50 μl assay buffer or antag-
onist, 3 min readout, addition of 50 μl agonists, and rea-
dout for 60 min. Max-min fluorescence signals before the
second addition and at the end of the experiment were
obtained.
Outside-out patch recording
Before forming cell-attached patches from HeLa cells
expressing TRPA1 or TRPM8, pipette offset was adjusted
to give a zero current value. Outside-out patches with the
least amount of leak were used, as judged by the very
small DC shift (<5 mV) of the basal current at different
membrane potentials. Currents were recorded using
AxoPatch200B. The pipette solution contained (mM):
140 NaCl, 1 MgCl2, 5 mM EGTA, and 10 HEPES (pH 7.3).
For experiments with NMDG+, the bath solution con-
tained (mM): 150 mM NMDG+, 115 mM Cl-, 5 mM
EGTA, and 10 HEPES (pH 7.3). For Cl- replacement exper-
iments, the bath contained 150 mM NMDG+, 62 mM
EGTA and 10 HEPES (pH 7.3). Patch membrane potential
was held at -80 mV, and then a voltage ramp from -140
mV to 0 mV (500 ms duration) was applied every 3 sec-
onds. Current was filtered at 1 kHz using 8-pole Bessel fil-
ter (-3 dB; Frequency Devices) and transferred directly to
a computer using the Digidata 1320 interface (Axon
Instruments) at a sampling rate of 10 kHz. Permeability
ratio (PX/PNa) was calculated using the equation: PX/PNa =
([X]o/[Na]o)￿ exp(ΔErev ￿F/RT); where ΔErev represents the
shift in Erev after addition of AITC in NMDG+ external/Na+
internal solution, and F/RT is 0.040 mV-1. The activity
coefficient of Na+ and NMDG+ was taken as 0.75 and 0.81,
respectively. Student's t-test was used with p < 0.05 as the
criterion for significance. Data are represented as mean ±
S.E. unless specified otherwise.
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